These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 23900220)

  • 1. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.
    Bae JM; Kim JH; Cho NY; Kim TY; Kang GH
    Br J Cancer; 2013 Aug; 109(4):1004-12. PubMed ID: 23900220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum.
    Yamauchi M; Morikawa T; Kuchiba A; Imamura Y; Qian ZR; Nishihara R; Liao X; Waldron L; Hoshida Y; Huttenhower C; Chan AT; Giovannucci E; Fuchs C; Ogino S
    Gut; 2012 Jun; 61(6):847-54. PubMed ID: 22427238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
    Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
    Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.
    Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
    Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.
    Kim JH; Shin SH; Kwon HJ; Cho NY; Kang GH
    Virchows Arch; 2009 Dec; 455(6):485-94. PubMed ID: 19911194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
    Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
    Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between molecular subtypes of colorectal cancer and patient survival.
    Phipps AI; Limburg PJ; Baron JA; Burnett-Hartman AN; Weisenberger DJ; Laird PW; Sinicrope FA; Rosty C; Buchanan DD; Potter JD; Newcomb PA
    Gastroenterology; 2015 Jan; 148(1):77-87.e2. PubMed ID: 25280443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.
    Kim JH; Kang GH
    World J Gastroenterol; 2014 Apr; 20(15):4230-43. PubMed ID: 24764661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
    Kohonen-Corish MR; Tseung J; Chan C; Currey N; Dent OF; Clarke S; Bokey L; Chapuis PH
    Int J Cancer; 2014 Jun; 134(12):2820-8. PubMed ID: 24259266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
    Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
    Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.
    Fu T; Pappou EP; Guzzetta AA; Jeschke J; Kwak R; Dave P; Hooker CM; Morgan R; Baylin SB; Iacobuzio-Donahue CA; Wolfgang CL; Ahuja N
    Clin Cancer Res; 2012 Sep; 18(17):4743-52. PubMed ID: 22825585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
    J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
    Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
    Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
    Ogino S; Nosho K; Kirkner GJ; Kawasaki T; Meyerhardt JA; Loda M; Giovannucci EL; Fuchs CS
    Gut; 2009 Jan; 58(1):90-6. PubMed ID: 18832519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
    Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
    PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.